Card image cap
Algernon launches new chronic kidney research program

Algernon Pharmaceuticals, a Canadian clinical stage drugmaker which has collaborated with Zhejiang Ausun Pharmaceutics of China to manufacture and supply its repurposed drug candidate NP-251 (Repirinast), has  launched a  new chronic kidney disease (CKD) research programme. As part of the new research, Algernon will investigate Repirinast use in acute interstitial nephritis as it showed a modest improvement in combination with telmisartan in lowering blood pressure.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment